Liposomes are nanoparticles used in drug delivery that distribute over several days in humans and larger animals. Radiolabeling with long-lived positron emission tomography (PET) radionuclides, such as manganese-52 ( 52 Mn, T½ = 5.6 days), allow the imaging of this biodistribution. We report optimized protocols for radiolabeling liposomes with 52 Mn, through both remote-loading and surface labeling. For comparison, liposomes were also remote-loaded and surface labeled with copper-64 ( 64 Cu, T½ = 12.7 h) through conventional means.
obtained by modern imaging techniques, such as positron emission tomography (PET). Since therapeutically relevant long-circulating liposomes have plasma half-lives of about 10-20 h in mice, the distribution from the blood stream to accumulating organs occurs within 2-3 days in murine models [8] . This makes the positron-emitting radionuclide 64 Cu (t ½ = 12.7 h, E mean = 278 keV) well-suited for preclinical PET imaging in small animals. However, the long-term fate and clearance of liposomes occurring after the initial 2-3 day distribution phase ("postdistribution") cannot be quantified using 64 Cu. Moreover, the plasma half-life of liposomes is extended in larger animals, being about 30-90 h in humans [9] . Therefore, comprehensive PET studies of liposomes in animal models beyond rodents also require longer-lived radionuclides.
As recent technological advances have made the use of the PET radionuclides zirconium-89 ( 89 Zr, t½ = 3.3 days) and iodine-124 ( 124 I, t½ = 4.2 days) feasible, these have garnered widespread interest in preclinical PET imaging, especially for antibody imaging in the case of 89 Zr [10] [11] [12] . However, implementation of these radionuclides in nanomedicine and in general has been limited due to the challenging radiochemistry of the highly oxophilic 89 Zr + 4 ion, and the cascade gamma photons and in vivo deiodination of 124 I, making imaging with these two radionuclides suboptimal. Manganese-52 ( 52 Mn, t½ = 5.6 days) has therefore recently gained interest. In addition to its long physical half-life, 52 Mn has a high positron branch (29.4%) compared to 64 Cu (17.9%) and a low positron energy (E mean = 242 keV)
which gives a short positron-range and high resolution PET images [13] . In addition, the straight-forward radiochemistry of 52 Mn, allows the use of standard chelators such as EDTA, DTPA and DOTA. Further, our and associated groups recently reported procedures for preparing 52 Mn in purities high enough for use in PET radiotracers such as liposomes [14, 15] . Its facile chelation by DOTA was also reported, in addition to preliminary evidence for good in vitro and in vivo stability of the Mn-DOTA chelate. These properties make 52 Mn highly useful in preclinical PET imaging, although its high gamma dose may discourage use in humans.
Efficient radiolabeling of liposomes can be achieved in two general ways. Either the radionuclide is loaded into the aqueous core of the liposome, known as remote-loading (Fig. 1) . Using this technique, 64 Cu has been shown to cross the liposomal membrane and be chelated by encapsulated DOTA with excellent (> 95%) radiolabeling yields [7] . In addition, Edmonds et al. recently reported a procedure for remoteloading 52 Mn through encapsulated metal-complexing drugs [16] . Alternatively, radiometals can be bound by chelators on the liposome surface, a method that has also been reported for 64 Cu using several different chelators [17, 18] . In order to rely on results from such surfacelabeling ( Fig. 1) , the stabilities of the employed chelates must be ascertained. Suboptimal stability will result in the release or transchelation of free radiometal with biodistributions that differ from the investigated tracer [19, 20] . Indeed, the stability of radiometal-chelator complexes placed on the surface of nanoparticles, on antibodies, peptides or small molecules, is paramount for conducting precise quantitative studies. However, the stability of radiometal-chelator complexes exposed directly to the bloodstream is still debated. This is especially true for the 64 Cu-DOTA chelate, one of the most used radiometal radiolabeling strategies in both research and the clinic [21] [22] [23] . As a result, a general reluctance to employ DOTA in imaging studies has been expressed, over concerns of release of the radionuclide from the chelate [24] . Cu-surface). All four were prepared as the DOTA chelates, and used to demonstrate a new liposome-based concept for the realistic in vivo evaluation of radiometal-chelate stability. By preparing remote-loaded liposomes, where the chelate is effectively shielded from the bloodstream, and comparing these with surface-labeled chelates that are exposed to the bloodstream, an analysis of the biodistribution and plasma excretion can be used to assess chelate stability. In the present study, this concept was used to investigate the stability of 64 Cu-DOTA and 52 Mn-DOTA. 
Materials
All chemicals where purchased from Sigma Aldrich, unless otherwise noted. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) was purchased from Avanti Polar Lipids. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono-N-hydroxysuccinimide ester (DOTA-NHS ester) was purchased from Macrocyclics, Inc. Premixed stealth liposome mixture (HSPC:Chol:DSPE-PEG2k 565:382:53, molar ratio) was purchased from Lipoid. All chemicals and reagents were of analytical grade, obtained from commercial sources and used without further purification. Sephadex G-25 PD-10 columns (8.3 mL bed volume) were purchased from GE Healthcare. All water was collected from a Milli-Q system (Millipore), unless otherwise noted. Ionophores 8-hydroxyquinoline (8-HQ), 2-hydroxyquinoline (2-HQ), 5,7-diiodo-8-hydroxyquinoline (8-HQ-2I), 5,7-dichloro-8-hydroxyquinoline (8-HQ-2Cl) were purchased from Sigma Aldrich (Chart 1). Hiruidin tubes were purchased from Roche, and Zymosan A from Saccharomyces cerevisiae, from Sigma Aldrich. The ELISA kit was purchased from Quidel and measured on a Victor3 microplate reader (Perkin Elmer).
All radio-TLC analyses were performed on silica gel 60 F254 plates (Merck) with 5% (w/v) NH 4 OAc in H 2 O-MeOH (1:1) as eluent, unless otherwise noted ( 52 Mn-surface was analyzed on cellulose). Quantification of radiotraces was achieved on a MiniGita Star using a Beta Detector GMC probe (both Raytest), or on a Cyclone Plus Storage Phosphor System (Perkin-Elmer). Radioactivity was measured using a Veenstra Instruments dose calibrator VDC-505. Metal content of radioactive preparations was quantified with an ICAP 7000 ICP-OES (Thermo Scientific). Liposome sizes were measured by dynamic light scattering (DLS) on a ZetaPALS (Brookhaven). Liposomes were sized by pressure extrusion using a 10 mL LIPEX thermobarrel pressure extruder (20 bar nitrogen pressure) [7] . Lipid concentrations were determined by an iCAPQ ICP-MS (Thermo Scientific).
An isotonic TRIS-saline buffer (ISO-TRIS) containing tris(hydroxymethyl) aminomethane (TRIS, 10 mM) and NaCl (150 mM) was prepared and adjusted to pH 7.8 with HCl/NaOH (osmolality: 280 mOsm/kg). An isotonic HEPES-saline buffer (ISO-HEPES) containing 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 10 mM) and NaCl (150 mM) was prepared by mixing molar equal amounts of sodium HEPES salt and free acid HEPES, for a final pH of 7.4-7.5 and osmolality of 292 mOsm/kg. For EDTA challenge, a 1.0 mM EDTA solution in ISO-HEPES was used (pH 7.4).
Preparation of 52
Mn and 64 Cu 52 Mn was produced by proton irradiation of natural chromium using a PETtrace cyclotron (GE Healthcare), following a previously described procedure [15] . In brief, the irradiated chromium was dissolved in hydrochloric acid, and the under argon flow for use in radiolabeling, as previously described [25] .
Synthesis of DSPE-DOTA
DOTA-NHS ester (34 mg, 45 μmol) and DSPE (28 mg, 37 μmol) were dissolved in dichloromethane (8 mL) . N,N-diisopropylethylamine (140 uL, 0.84 mmol) was added and the reaction proceeded overnight at room temperature (RT). The solvent was removed under reduced pressure and the product purified by semi-preparative HPLC (Waters 600 Pump & Controller, Waters 2489 UV/Visible detector) using a Waters XTerra® C 8 5 μm (10 × 150 mm) column. Eluent: (A) 5% acetonitrile + 0.1% trifluoroacetic acid in water, (B) 0.1% trifluoroacetic acid in acetonitrile. Gradient profile; linear gradient from 50% B to 100% B over 15 min followed by 5 min at 100% B. Flow rate; 5 mL/min. DSPE-DOTA was isolated as a broad peak from 11 to 18 min. Fractions were analyzed by MALDI-TOF and those containing the desired product and no detectable impurities were pooled. The product was lyophilised to obtain a white powder ( 
Preparation of liposomes (DOTA1%, LIP405, LIP780)
For surface loading: A stealth lipid mixture containing 1.0 mol% DSPE-DOTA (HSPC:Chol:DSPE-PEG2k:DSPE-DOTA 560:378:52:10, molar ratio) was freeze-dried from tert-butanol:water (9:1). The obtained lyophilizate was hydrated with an aqueous ISO-HEPES buffer (see Section 2.1) at 65°C for 60 min and subsequently sized by pressure extrusion, furnishing DOTA1% liposomes. The average liposome size was 102 nm (PDI 0.005) as measured by DLS, and the lipid concentration was 27 mM based on measuring the phosphorous content by ICP-MS. For remote loading: Liposomes entrapping 10 mM DOTA were prepared with internal pH values of 4.05 (LIP405) or 7.80 (LIP780). Stealth liposome mixture was hydrated in either a DOTA-HEPES buffer (10 mM HEPES, 150 mM NaCl, 10 mM DOTA, pH 4.05, 304 mOsm/kg) or a DOTA-TRIS buffer (10 mM TRIS, 150 mM NaCl, 10 mM DOTA, pH 7.80, 299 mOsm/kg), at 65°C for 60 min. Subsequently the liposomes were sized by pressure extrusion. The external medium of the DOTA-HEPES liposomes was replaced with ISO-HEPES buffer and the external media of the DOTA-TRIS liposomes with ISO-TRIS using dialysis or tangential flow filtration, as previously described [7] . The size and lipid concentration were 99 nm (PDI 0.033) and 63 mM for the DOTA-HEPES liposomes and 102 nm (PDI 0.043) and 14.7 mM for the DOTA-TRIS liposomes. 8HQ-C2l, 128 μL, 50 μM). The mixture was dried in HPLC vials at 120°C under an argon stream (maximum 10 min). To the dry mixtures was added LIP480 or LIP780 (320 μL, 10 mM lipid) and the reaction mixtures were magnetically stirred at 55°C. At specified time-points (typically 1 h, 2 h and 3 h), the mixtures were analyzed by radio-TLC and size-exclusion chromatography (SEC). For SEC analysis, an aliquot (80 μL) was mixed with a solution of EDTA in ISO-HEPES buffer (1.0 mM EDTA, 80 μL) and allowed to equilibrate for 5-10 min.
Mixtures were then applied to a PD-10 cartridge and eluted with ISO-HEPES. Two consecutive fractions of 5.5 mL each were collected and their radioactivity quantified on a dose-calibrator. The PD-10 derived encapsulation efficiency was determined as the ratio of the radioactivity in the liposome fraction (fraction one, 5.5 mL) to the total radioactivity in fraction one and two combined (11 mL). Radio-TLC showed two spots corresponding to Mn-DOTA activity to the total radioactivity in all peaks combined. After 3 h, the remaining mixture was mixed 1:1 with a solution of EDTA in ISO-HEPES (1.0 mM EDTA) and allowed to equilibrate for 24 h at room temperature (RT). The mixture was then analyzed by PD-10 as described above. The loading experiments were conducted at 10 mM lipid, 20 μM ionophore and a 52 Mn radioactivity concentration of 13 MBq/mL and performed in triplicate.
Loading of 64 Cu: Remote-loading of 64 Cu into liposomes was conducted as previously described [3, 7] . These mixtures were heated to 55°C while stirred magnetically. After 1 h, 2 h and 3 h, the mixtures were analyzed by radio-TLC on cellulose (eluted in 100 mM citrate, pH 8.4) and on PD-10 columns as described in Section 2.5. 52 Mn-DOTA-DSPE was shown not to elute on TLC, whereas free 52 Mn could be quantified as 52 Mn-Citrate (Rf = 1.0). Subsequently, a 24 h EDTA challenge study was conducted as also described in Section 2.5. Surface-labeling with 64 Cu: A dispersion of DOTA1% liposomes in ISO-HEPES (500 μL, 10 or 20 mM lipid) was added to dry 64 CuCl 2 (98-106 MBq). The resulting mixtures were magnetically stirred at 55°C. At 1 h, 2 h and 3 h, the reaction mixtures were challenged with 1 mM EDTA in ISO-HEPES as described in Section 2.5. Radio-TLC and PD-10 were conducted, followed by a 24 h EDTA challenge as described in Section 2.5.
64
Cu-DOTA-DSPE was shown not to elute on TLC, whereas free 64 Cu could be quantified as 64 Cu-EDTA (Rf = 0.7). These experiments were done in triplicate (n = 3) for each lipid concentration.
Preparation of radiolabeled liposomes for in vivo experiments
All radiolabeled liposome preparations for in vivo use were 20 mM lipid, 2.0 mL and 12. (520 μL) and the mixture was magnetically stirred at 55°C for 10 min. DOTA1% liposomes (1480 μL, 27 mM lipid) was added and the stirring was continued for 2 h at 55°C. PD-10 analysis and radio-TLC were conducted as described above (Section 2.5) showing 99% and 100% loading efficiency respectively.
64
Cu-remote: To a vial containing dry CuCl 2 (360 MBq) was added LIP780 liposomes (14.7 mM lipid, 1750 μL) and the reaction mixture was magnetically stirred at 55°C for 75 min. Then, empty liposomes were added to reach a lipid concentration of 20 mM. PD-10 analysis and radio-TLC were conducted as described above (Section 2.5) showing 97% and 100% loading efficiency respectively.
64 Cu-surface: To a vial containing dry CuCl 2 (360 MBq) was added DOTA1% liposomes (27 mM lipid, 1480 μL). The reaction mixture was magnetically stirred at 55°C for 2 h. Finally, an aliquot of the reaction mixture (80 μL) was mixed with 1.0 mM EDTA in ISO-HEPES (80 μL) and after 5-10 min of equilibration, PD-10 and radio-TLC analyses were conducted as described above (Section 2.5). A loading efficiency of 93% and 100% was observed for PD-10 and TLC respectively. The loading efficiency was also analyzed on HPLC-SEC (Sephadex 25G superfine, prepacked in a GE Healthcare Tricorn 5/200 column, 0.4 mL/min ISO-TRIS), which showed 98% loading efficiency.
Animal model
All experimental procedures were approved by, and conducted under the guidelines of The Danish Animal Experiments Inspectorate. Immunocompetent Balb/C mice (Charles River Laboratories) were inoculated subcutaneously with 3 × 10 5 CT26 cancer cells (murine colon carcinoma, ATCC, Virginia, US) in 100 μL medium in the right flank. Tumor sizes were calculated from the formula tumor size = 0.5·(
where L is the length and W is the width of the tumor, measured by external caliper. The tumors were monitored and included in the study when reaching a tumor size of~150 mm 3 .
PET imaging and data analysis
Mice were slowly injected via the tail vein with 200 μL radiolabeled liposomes containing either 12-13 MBq 64 Cu or 2-3 MBq 52 Mn. During the scan procedures all mice were kept anaesthetized with 3% sevoflurane (Abbott Scandinavia AB, Solna, Sweden) mixed with 35% O 2 and 65% N 2 and placed on a heating pad. Two mice were positioned side-by-side, separated by a 6 mm polystyrene block for PET/CT imaging using an Inveon® small animal PET/CT system with CT based PET image attenuation (Siemens Medical Systems, Malvern, PA, USA). The protocol included a CT scan followed by a PET scan. Acquisition times for PET scans were performed to provide sufficient numbers of counts and ranged from 5 to 15 min. Reconstruction of PET scans were performed using maximum a posteriori Mn isotope was 40 min, 2 h, 6.5 h, 16 h, 24 h, and 30 h after injection (all groups). Additionally, three time points were imaged for the 52 Mn isotope at day 4, 6, and 8 after injection (group 1 and 2).
Image analysis was performed using commercially available Inveon software (Siemens Medical Systems, Malvern, PA, USA). Regions of interest (ROIs) were manually drawn based on the co-registered PET/ CT images. The following ROIs were constructed; tumors (complete volume delineated), liver, spleen, bladder and blood. Blood activity was estimated from a constructed ROI covering the ventricles of the heart. ROIs were subsequently segmented to only include the voxels displaying above 80% of maximum activity with the original ROI and clearly delineated the heart ventricles. For the 52 Mn images ROIs were drawn to cover the femoral bone and these were subsequently segmented, based on CT, to exclude solid bone and only include central located 
Results and discussion

Radiochemistry
We prepared liposomes surface labeled or remote loaded with 52 Mn or 64 Cu and compared the resulting four liposome types head to head in vivo in a murine tumor model to assess the stability of the DOTA chelates. As new methodology for 52 Mn radiolabeling of liposomes is reported here, these procedures were investigated in detail and optimized.
General radiochemistry
Radiolabeling efficiencies were measured by both PD-10 and radio-TLC, giving slightly different results. The reason for this is imperfect separation of small molecules and liposomes by PD-10, resulting in a slight overlap of the large molecule and the small molecule peaks, which occurs between 5.5 and 6.0 mL. Since we only considered the elution up to 5.5 mL as belonging to the liposomes, the PD-10 results are generally artificially lower than the TLC results. In the preparation of 64 Cu-surface for in vivo experiments PD-10 analysis only gave 93% labeling efficiency (TLC gave 100%), for which reason this preparation was also analyzed on SEC-HPLC, giving 98% labeling efficiency. Mn bound to liposomes (non-eluting). Note that the ionophore-radiometal complexes do not elute in the employed TLC systems. Mn-remote) In this method, loading of the radionuclide is facilitated by a strong transmembrane cation gradient as previously described for 64 Cu [7] . In initial attempts, liposomes entrapping DOTA were loaded with 52 Mn without the use of ionophores, which resulted in a poor loading efficiency (< 30% on PD-10 and < 20% on TLC, see Control in Fig. 2 A-B) . Because of this, the ionophores 2-HQ and 8-HQ were included to assist the diffusion of 52 Mn across the lipid bilayer. Little increase in loading efficiency was gained by adding 2-HQ (data not shown). However, the use of 8-HQ resulted in increased loading (> 70% on PD-10, 3 h loading) for liposomes entrapping DOTA at pH 7.8 ( Fig. 2 A-B) . In order to push the equilibrium of the loading/exchange reaction (Mn (IO) x + DOTA(lip) ⇄ MnDOTA(lip) + x IO, where IO is short for ionophore) further, two optimization strategies were devised. In one approach, the 52 Mn-ionophore complex stability was reduced by including chloro (8-HQ-2Cl) or iodo (8-HQ-2I) electron withdrawing substituents on the quinolone ring of the ionophore. In the second approach, the binding affinity of the entrapped chelator and ionophore was reduced by lowering the pH value and hence increasing the protonation of these inside the liposome lumen. For liposomes entrapping DOTA at pH 4.0 or pH 7.8, improved loading efficiency (> 95% loading on PD-10 and > 98% loading on Radio-TLC) was obtained when 8-HQ-2Cl was used as ionophore ( Fig. 2 A-B) . Equally high loading efficiencies were obtained for liposomes entrapping DOTA at pH 4.0 when using 8-HQ and 8-HQ-2I as ionophores. 8-HQ-2I was only tested for liposomes entrapping DOTA at pH 4.0 as its poor solubility in EtOH limited its use.
Complete loading (> 95%) was reached within the first hour in all cases except for 8-HQ at pH 7.8. In the latter case, a gradual increase in loading efficiency was observed as a function of time. These results showed that the loading efficiency, and thereby the exchange of the radiometal from the ionophore complex to DOTA, could be optimized by destabilization of the 52 Mn-ionophore complex using electronwithdrawing substituents. Similar reduction in the binding affinity of copper with 8-HQ versus 8-HQ-2Cl has previously been reported [26] which substantiates the claim of destabilization of the 52 Mn-ionophore complex. Moreover, a reduction of the pH inside the liposomes from 7.8 to 4.0 resulted in complete loading for 8-HQ, 8-HQ-2Cl and 8-HQ-2I. Both remote-loaded and surface-labeled liposomes exhibited high stability of the radiolabel when exposed to an EDTA challenge for 24 h. < 5% decline in loading efficiency ( Fig. 2A-B) was observed between the 3-and 24-h time-point. Hence, unloading of 52 Mn in vivo is highly unlikely as long as the liposomes remain intact in vivo, which they have been shown in previous studies to be [3, 25] . The high loading efficiencies (> 95%) obtained for 52 Mn in this study compares to previous results obtained for the remote loading of 64 Cu [7, 27] . In previous studies, we tested stealth liposomes remote-loaded with 64 Cu-DOTA both with and without ionophores against serum, finding that no leakage of the radioactivity occurred [3] . Likewise, the stability of the DOTA complexes of 52
Mn and 64
Cu against serum has been evaluated previously and found to be excellent [15, 28] . For these reasons, high serum stability of both surface-labeled and remote-loaded liposomes was expected.
The impact of the ionophore concentration on the loading rate was investigated using radio-TLC (Fig. 2C) . The loading rate was shown to increase with increasing ionophore concentration. The metal ion content of the loading rate assay was estimated to be about 4.3 μM metal ions, including 0.27 μM Mn. Thus, addition of 2 μM ionophore represents a small excess compared to Mn but is insufficient to chelate the total number of cations present. Hence, by adding 10-25-fold higher ionophore concentrations, all cations are likely to be chelated by the ionophore and the loading completes within 5-30 min (Fig. 2C) . The loading rate and optimal amount of ionophore thus depends on the metal ion content of the sample and therefore the radionuclide purity. Remote loading of 64 Cu is described in-depth in previous publications
and not discussed here [7] . Based on these findings, a conserved ionophore/lipid ratio of 20 μM/10 mM was used for remote loading 52 Mn into the liposomes used for in vivo studies.
Surface labeling of 64
Cu and 52 Mn
In this method, radiolabeling was facilitated by a high affinity chelator (DOTA) which had been covalently bound to a lipid that was incorporated into the liposome surface (Fig. 1) . This method has been described by Seo et al. [18] . For this purpose, the lipid conjugate DOTA-DSPE was synthesized, as the DSPE anchor had been previously shown to be stably embedded in liposome membranes composed of HSPC, Cholesterol and DSPE-PEG2k [18] . Initially, radiolabeling was conducted at 13 MBq 52 Mn/mL using 10 mM liposomes, which resulted in partial labeling (Fig. 2D) . By doubling the lipid concentration, and hence the amount of DOTA-DSPE, quantitative radiolabeling (> 95%) was obtained within the 3 h incubation period. For 64 Cu, complete loading (> 94% on SEC and > 99.5% on TLC) was obtained for both 10 and 20 mM liposomes after 1 h, and the loading efficiency remained high after 2 and 3 h of incubation (data not shown). For both 52 Mn and 64 Cu, a 24 h EDTA challenge of the surface labeled liposomes resulted in < 4% decrease in the loading efficiency. The observed loading efficiency and stability of the DOTA-DSPE functionalized liposomes were fully comparable with remote loaded liposomes for both 52 Mn and 64 Cu.
In vivo evaluation
All four liposome types were intravenously injected into CT26-tumor bearing mice. In all cases, 200 μL liposome dispersion (20 mM lipid) was administered, corresponding to 160 μmol lipid/kg. This is a 5-fold higher lipid dose than normally used for imaging in our group [7, 25, 29] . Doses within this range may suffer less first pass clearance [30] . Representative PET/CT images of the 52 Mn-and 64 Cu-liposome scans at the different time-points are illustrated in Fig. 3 . Regions-ofinterest were marked and quantified ( Fig. 4A-E ) and compared to postmortem gamma-counted activity levels (Fig. 4F ). All accumulation values are reported as percent injected dose per gram tissue (%ID/g). The comparison of the four liposome types was used to assess the stability of the 64 Cu-DOTA and 52 Mn-DOTA chelates. Liposomes represent a unique platform for such in vivo analyses as they allow the sequestration of a given radiometal-chelate into two isolated compartments, encapsulated or surface-conjugated. The encapsulated remote-loaded chelate is completely shielded from interactions with bloodstream components, preventing transchelation of free radiometal and enabling immediate reuptake by resident free DOTA in case of release from the chelate. On the other hand, the surface-conjugated chelate, DOTA-DSPE, is situated at the lipid bilayer interface and is in contact with the bloodstream, making it vulnerable to the conditions that might cause instabilities of the chelate during in vivo imaging. Further, since both types are longcirculating, this setup allows their comparison and analysis of stability differences over hours to days, providing a scenario that mirrors a realistic preclinical/clinical setting.
Analysis of chelate stabilities
Radioactivity levels by PET and ex vivo well-counting for all analyzed organs are seen in Fig. 4 . Overall, the four liposome types were observed to follow similar clearance from the blood pool, with little difference between them (Fig. 4A, for Cu-remote (6.5 h: p < 0.0001, 16 h: p = 0.03 and 24 h: p = 0.004). The two remoteloaded formulations, which were expected to have the most stable radiolabels due to their shielding from the surroundings, exhibited largely identical blood values, demonstrating the stability of these In summary, the in vivo PET blood data showed generally faster elimination of the radiolabel for the two surface-labeled types, with resulting lower blood values and half-lives. This was more pronounced for 52 Mn-surface than for 64 Cu-surface. Accordingly, the blood data suggest that the 52 Mn-DOTA chelate may be unstable when exposed to plasma components. The possible mechanisms of this indicated instability are currently unknown and will require further studies. From the obtained data, it is inconclusive whether this also applies to 64 Cu-DOTA. For the remaining organs, no clearly interpretable patterns were found, except for the urinary bladder. The radioactivity in the urine was observed to be markedly higher for 64 Cu-remote and 52
Mn-remote in the first 5 h of imaging. Since chelates of radionuclides are known to undergo renal excretion [25] , this could stem from limited liposomal rupture and release of cargo as a result of opsonization in the first hours after injection [31] . With chelates bound to lipid molecules, as is the case for the two surface-labeled types, such renal excretion would be unlikely. High initial urinary excretion of free radionuclide chelates inside liposomes has been previously observed [32] . Mn may be extracted from DOTA after metabolism of the liposomes, and end up in the pancreas, a known sink organ for free 52 Mn [14] . This also hints at a somewhat compromised in vivo stability of 52 Mn-DOTA.
In both cases of surface-labeling, there is the theoretical possibility of migration of the radiolabeled lipids to other endogenous sites. This however, is not expected to occur for chelator-functionalized lipids with double C18 anchors [18] . In addition, the slightly faster clearance of the surface-labeled liposomes could be caused by increased uptake by immune cells due to the presence of charged DOTA on the surface. For this reason we measured complement activation of the DOTA1% liposomes (DOTA on surface) and compared with LIP780 (DOTA in aqueous compartment). For full results, see Supplementary materials S4. Overall, a 2.1 and 1.6-fold increase in SC5b-9 compared to background was observed for the DOTA1% and LIP780 formulation respectively. This is a less pronounced activation profile compared to results published by Wibroe et al. that reported a 2-40 fold increase in SC5b-9 levels for a range of liposomal doxorubicin formulations [33] . Accordingly, surface-functionalized DOTA causes slightly higher complement activation, but whether this limited effect could be a factor in the enhanced clearance is currently unknown.
In between target and non-target organs when compared to other chelators [34, 35] . This is in contrast to a generally reported high serum stability of the 64 Cu-DOTA chelate [36, 37] . It has been suggested that the facile reduction of Cu(II) to Cu(I), with consequent dechelation, may be implicated in the in vivo instability [38] . Since Mn(II) is fairly easily converted to Mn(IV), it may be speculated that redox processes also play a role in the observed instability of 52 Mn-DOTA. In spite of the apparent in vivo instability of 64 Cu-DOTA, it is successfully employed in the clinic with good image quality [39, 40] . In this study we found some evidence that a 64 Cu-DOTA complex conjugated to the surface of lipo- Mn into the bloodstream may occur. This is supported by Graves et al. who found the blood concentration to be around 4%ID/g at the 96 h time-point after injection of free 52 Mn [14] . We observed an average of 3.3 ± 1.0%ID/g at this time. We found no significant difference between the two types at these late time-points. The tumor accumulation of the two 52 Mn-labeled types increased . The faster clearance of 52 Mn-remote may be caused by destruction of the liposomes after cellular uptake, followed by easier washout of the highly hydrophilic 52 Mn-DOTA chelate. Long-term imaging of the two 52 Mn liposome types showed elimination from the liver and spleen after 30 h at similar rates for the two.
With the current interest in using radiolabeled liposomes as theranostic PET radiotracers for predicting the presence of the EPR effect in a clinical setting in human subjects, the choice of radionuclide becomes relevant. Due to the longer time-span of biodistribution in humans, longer-lived radionuclides may be preferable. In this case, a reduced patient dose is received if the accumulated radioactivity is subsequently eliminated, especially from highly accumulating organs such as liver and spleen. These results show that this may be the case. In order to showcase the dosimetric significance of elimination from organs and the general use of long-lived PET radionuclides dosimetry calculations were made. These are presented in Supplementary materials S5, and showed that the received dose from using 52 Mn or 64 Cu depends heavily on the time of image recording. With imaging times after around 69 h post-injection, 52 Mn was found to have favorable dosimetry.
General biodistribution
The highest observed tumor accumulation values for all four liposome types were around 4%ID/g, with limited significant difference at all time-points between the groups. The peak tumor accumulations reached by all four groups are similar to previously reported values for liposomes in murine tumor xenograft models [11, 25, 29] . A discussion of tumor accumulation data can be found in Supplementary materials S6.
Liver accumulation was similar for all four liposomes types, with high initial values around 25%ID/g, increasing until 30 h, reaching values around 30-45%ID/g. These values were higher than typically reported data for liposomes in murine models, potentially due to the mice strain used in the study at hand. Further studies are needed to decipher the mechanisms underlying this observation, which is beyond the scope of this paper. Few clear patterns of significant difference between the four liposome types were identified, but 52 Mn-surface exhibited higher liver accumulation than the other types and was different from 64 Cu-remote (lowest liver accumulation) at 6. Cu-remote at all time-points (p < 0.05). However, there is no clear reason for this, as these two liposome types should have identical surface characteristics.
In addition to the %ID/g values reported here, absolute accumulation data (%ID) can be found in Supplementary materials S7. In this section the total body radioactivity as a function of time is also provided ( Fig. S3E and F) . The total radioactivity accounted for was around 100% at the start of scans and was eliminated with a half-life of about 50 h, largely independent of liposome type.
The ex vivo accumulation data for tumor, spleen and liver (Fig. 4F ) mirrored the values obtained by PET imaging, with somewhat lower values for well-counting of 52 Mn-liposomes, due to the passing of an additional three days after the last PET time-point (8 days). Pancreas was included since free 52 Mn has been reported to accumulate strongly in this organ [14] , while free 64 Cu is known to accumulate in liver [20, 41] .
Conclusion
We have successfully developed an ionophore assisted method for 
